

**Information for patients who have had their COPD
medicine changed to Trelegy ▼ Ellipta (fluticasone
furoate/umeclidinium/vilanterol)**

Information for patients who have had their COPD medicine changed to Trelegy▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

What is in my Trelegy Ellipta inhaler?

Your Trelegy Ellipta inhaler contains three types of inhaled medicines:



- A corticosteroid
- A long acting β_2 agonist
- A long acting muscarinic antagonist

Why am I receiving one maintenance inhaler?

Previously you will have been prescribed more than one maintenance inhaler to deliver these three types of inhaled medicine. With Trelegy Ellipta you will now receive these three medicines from one inhaler.

How often should I use my Trelegy Ellipta?

Your Trelegy Ellipta inhaler contains a 30 dose supply and is to be used every day, one inhalation, once a day, at the same time each day.

Do not use your Trelegy Ellipta inhaler to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting inhaler (such as salbutamol).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get via the yellow card scheme at: www.mhra.gov.uk/yellowcard

How do I use my Trelegy Ellipta inhaler?

You do not need to prepare your Trelegy Ellipta inhaler in any special way, just follow these step-by-step instructions:

Only open the cover once you are ready to take a dose. If you open and close the cover without inhaling the medicine, the dose will be lost.

Open



- Slide the cover down until you hear a **'click'**
- While holding the inhaler away from your mouth, breathe out as far as is comfortable

Inhale



- Put the mouthpiece between your lips, and close your lips firmly around it
- Take one long, steady, deep breath in and hold this breath for at least 3-4 seconds

Close



- Remove the inhaler from your mouth and breathe out slowly and gently
- Slide the cover upwards as far as it will go to cover the mouthpiece

Please Note:

- Within the inhaler packaging, the tray contains a desiccant sachet to reduce moisture. Throw this desiccant sachet away — don't open, eat or inhale it.
- It may not be possible to taste or feel the medicine, even when using the inhaler correctly.
- Do not shake the inhaler, block the air vents with your fingers, or breathe out into the inhaler.
- The dose counter will count down by one unit at a time.
- If the dose counter does not count down as you hear the 'click', the inhaler will not deliver the required dose. If this happens take your inhaler back to the pharmacy.

How to use:

- The purpose of this is to support your COPD patients who have had their medication changed from a multiple inhaler triple therapy combination to Trelegy Ellipta following a clinical review.
- A copy should only be provided to a patient once a decision to prescribe Trelegy Ellipta has been made/confirmed.
- The material has been designed to help patients familiarise themselves with their Trelegy Ellipta.
- To most effectively support your patients to take their Ellipta medicine, you may wish to use this in conjunction with an Ellipta demonstration device. Your GSK account manager will be able to order one of these for you. Alternatively, you can order these online at: www.hcp.gsk.co.uk/resources.
- A visual representation of the three steps required for your patients to use the Ellipta device correctly can be found in this document. These steps are closely aligned with the steps described in the Patient Information leaflet (PIL). We recommend that you read the Summary of Product Characteristics (SmPC)/PIL for further information on how to use the Ellipta inhaler, and advise the patient to read the PIL before using their medicine.

Practical considerations:

A number of factors should be considered when deciding whether to change a patient from one inhaled medicine to another within the same class:

- The licenses of the medicines in question must be reviewed for consistency.
- A number of patient factors such as ability to use the inhaler correctly and patient preference.
- Dosing regimens which may support adherence such as OD vs BD.
- As well as previous experience and response to therapy with particular medicines.

Regardless of the reason for a change in medicine GSK advocates that a patient should only have their medication changed following a face to face medical review. GSK believes that the patient should be involved in the decision making process, trained as appropriate on the new inhaler and clinically monitored to ensure that their condition continues to be managed appropriately after the change.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

INNOVIVA

Trelegy Ellipta was developed in collaboration with Innoviva Inc.
Trademarks are owned by or licensed to the GSK group of companies.
© 2018 GSK group of companies or its licensor.